Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-lpr/lpr mice

Immunology

Volumn 100, Issue 1, 2000, Pages 110-118

  Wu, W M ^a   Suen, J L ^a   Lin, B F ^b   Chiang, B L ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CONCANAVALIN A; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY CD3; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; HORMONAL THERAPY; IMMUNOMODULATION; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PERITONEUM EXUDATE; PRIORITY JOURNAL; SPLEEN; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; ANTIGENS, SURFACE; ASCITIC FLUID; AUTOIMMUNE DISEASES; CELL CULTURE TECHNIQUES; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ESTROGEN ANTAGONISTS; FEMALE; INTERLEUKIN-2; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPH NODES; MICE; PROTEINURIA; SPLEEN; SURVIVAL RATE; T-LYMPHOCYTE SUBSETS; TAMOXIFEN;

EID: 0034053286     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2000.00998.x     Document Type: Article

References (43)

1. 1. ANDREWS B.S., EISENBERG R.A., THEOFILOPOULOS A.N. et al. (1978) Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 148, 1198.
2. 2. EISENBERG R.A., TAN E.M. & DIXON F.J. (1978) Presence of anti-Sm reactivity in autoimmune mouse strains. J Exp Med 147, 582.
3. 3. STEINBERG A.D., KLINMAN D.M., KASTNER D.L. et al. (1978) Genetic and molecular genetic studies of murine and human lupus. J Rheumatol 14, 166.
4. 4. JONSSON R., TARKOWSKI A., BACKMAN K., HOLMDAHL R. & KLARESKOG L. (1987) Sialadenitis in the MRL-1 mouse: morphological and immunohistochemical characterization of resident and infiltrating cells. Immunology 60, 611.
5. 5. WATANABE-FUKNAGA R., BRANNAN C.I., COPELAND N.G., JENKINS N.A. & NAGATA S. (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314.
6. 6. CHU J.L., DRAPPA J., PARNASSA A. & EIKON K.B. (1993) The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransponson, ETn. J Exp Med 178, 723.
7. 7. SINGER G.G. & ABBAS A.K. (1994) The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1, 365.
8. 8. RENNO T., HAHNE M., TSCHOPP J. & MACDONALD H.R. (1996) Peripheral T cells undergoing superantigen-induced apoptosis in vivo expression B220 and upregulate Fas and Fas ligand. J Exp Med 183, 431.
9. 9. MORSE III H.C., DAVIDSON W.F., YETTER R.A., MURPHY E.D., ROTHS J.B. & COFFMAN R.L. (1982) Abnormalities induced by the mutant gene lpr: expansion of a unique lymphocyte subset. J Immunol 129, 2612.
10. 10. COHEN P.L. & EISENBERG R.A. (1991) Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 9, 243.
11. 11. BUTTA A., MACLENNAN K., FLANDERS K.C., SACKS N.P.M., SMITH I. & MCKINNA A. (1992) Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52, 4261.
12. 12. JORDAN V.C. (1993) Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 110, 507.
13. 13. JORDAN V.C. (1995) Third annual William L. McGuire Memorial Lecture. Studies on the estrogen receptor in breast cancer - 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 36, 267.
14. 14. NAYFIFLD S.G. (1995) Tamoxifen's role in chemoprevention of breast cancer: an update. J Cell Biochem 22 (Suppl.), 42.
15. 15. CHAKRAVARTY N. (1992) The roles of carmodulin and protein kinase C in histamine secretion from mast cells. Agents Actions 36, 183.
16. 16. COLLETTA A.A., BENSON J.R. & MICHAEL B. (1994) Alternative mechanisms of action of anti-estrogens. Breast Cancer Res Treat 31, 5.
17. 17. WISEMAN H. (1994) Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances. Trends Pharmacol Sci 15, 83.
18. 18. KNABBE C., ZUGMAIER G. & SCHMAHL M. (1991) Induction to transforming growth factor beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Am J Clin Oncol 14 (Suppl. 2), S15.
19. 19. BARAL E., NAGY E. & BERCZI I. (1995) Modulation of natural killer cell-mediated cytotoxicity by tamoxifen and estradiol. Cancer 75, 591.
20. 20. KANG Y., CORTINA R. & PERRY R.R. (1996) Role of c-myc in tamoxifen-induced apoptosis in estrogen-independent breast cancer cells. J Natl Cancer Inst 88, 279.
21. 21. O'BRIAN C.A., LISKAMP R.M., SOLOMAN D.H. & WEISTEIN I.B. (1985) Inhibition of protein kinase C by tamoxifen. Cancer Res 45, 2462.
22. 22. DRACH J., GSUR A., HAMILTON G. et al. (1996) Involvement of p-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-γ in normal human T lymphocytes. Blood 88, 1747.
23. 23. LAVIE Y., ZHANG Z.C., CAO H.T. et al. (1998) Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells. Int J Cancer 77, 928.
24. 24. LΦNNING P.E., HALL K., AAKVAAG A. & LIEN E.A. (1992) Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 52, 4719.
25. 25. STEINBERG A.D., ROTHS J.B., MURPHY D.E., STEINBER R.T. & RAVECHE E.S. (1980) Effects of thymectomy or androgen administration upon the autoimmune disease of MRL/Mp-lpr/lpr mice. J Immunol 125, 871.
26. 26. ROUBINIAN J.R., TALAL N., GREENSPAN J.S., GOODMAN J.R. & SUTERI P.K. (1978) Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/W F1 mice. J Exp Med 147, 1568.
27. 27. STHOEGER Z.M., BENTWICH Z., ZINGER H. & MOZES E. (1994) The beneficial effect of the estrogen antagonist, tamoxifen, on experimental systemic lupus erythematosus. J Rheumatol 21, 2231.
28. 28. DAYAN M., ZINGER H., KALUSH F. et al. (1997) The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations. Immunology 90, 101.
29. + and CD5 B cells of autoimmune NZB x NZW F1 mice. Clin Exp Immunol 106, 253.
30. 30. LIN L.C., CHEN Y.C., CHOU C.C., HSIEH K.H. & CHIANG B.L. (1995) Dysregulation of T helper cell cytokines in autoimmune prone NZB x NZW F1 mice. Scand J Immunol 42, 466.
31. 31. CHEN Y.C., YE Y.L. & CHIANG B.L. (1997) Establishment and characterization of cloned CD4 CD8 αβ TCR bearing auto-reactive T cells from autoimmune NZB/W F1 mice. Clin Exp Immunol 108, 52.
32. 32. MITENYI S., MULLER W., WEICHEL W. & RADBRUCH A. (1990) High gradient magnetic cell separation with MACS. Cytometry 11, 231.
33. 33. KAPLAN E.L. & MEIER P. (1958) Nonparametric estimation from incomplete observation. J Am Stat Ass 53, 457.
34. 34. IZUI S., KELLEY V.E., MASUDA K., YOSHIDA H., ROTHS J.B. & MURPHY E.D. (1984) Induction of various autoantibodies by mutant gene lpr in several strains of mice. J Immunol 159, 2265.
35. 35. ROUBINIAN J., TALAL N., SILTER P.K. & SADAKIAN J.A. (1979) Sex hormone modulation of autoimmunity in NZB/NZW mice. Arthritis Rheumatism 22, 1162.
36. 36. HOLMDAHL R. (1989) Estrogen exaggerates lupus but suppresses T-cell dependent autoimmune disease. J Autoimmunity 2, 651.
37. 37. SNAPPER C. & MOND J.J. (1993) Towards a comprehensive view of immunoglobulin class switching. Immunol Today 1, 15.
38. + T cells to lymphoproliferation and autoantibody production in MRL-lpr/lpr mice. J Exp Med 167, 1713.
39. 39. KOH D.R., HO A., RAHEMTULLA A., FUNG-LEUNG W.P., GRIESSER H. & MAK T.W. (1995) Murine lupus in MRL/lpr mice lacking CD4 or CD8 T cells. Eur J Immunol 25, 2558.
40. 40. WOFSY D., HARDY R.R. & SEAMAN W.E. (1984) The proliferating cells in autoimmune MRL/lpr mice lack L3T4, an antigen on 'helper' T cells that is involved in the response to class II major histocompatibility antigens. J Immunol 132, 2686.
41. 41. ALTMAN A., THEOFILOPOULOS A.N., WEINER R., KATZ D.H. & DIXON F.J. (1981) Analysis of T cells function in autoimmune murine strains: Defects in production and responsiveness to interleukin-2. J Exp Med 154, 791.
42. 42. LIANG H.E., HSUEH Y.P., WU C.C., HSU S.C., HAN S.H. & LAI M.Z. (1998) Atypical signal defects prevent IL-2 gene expression in lpr/lpr CD4 CD8 cells. J Biomed Sci 5, 297.
43. 43. RADVANYI L.G., RAJU K., SPANER D., MILLS G.B. & MILLER R.G. (1998) Interleukin-2 reverses the defect in activation-induced apoptosis in T cells from autoimmune lpr mice. Cell Immunol 183, 1.